{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:24:13Z","timestamp":1791537853694,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To date, the United States Food and Drug Administration (FDA) has approved four drugs to mitigate hematopoietic acute radiation syndrome and all four are repurposed radiomitigators. There are several additional drug candidates currently under evaluation that may also be helpful for use during a widespread emergency. One possible candidate is Ex-Rad, also known as ON01210, a chlorobenzyl sulfone derivative (organosulfur compound), which is a novel, small-molecule kinase inhibitor with demonstrated efficacy in the murine model. In this study, we have evaluated the metabolomic and lipidomic profiles in serum samples of nonhuman primates (NHPs) treated with Ex-Rad after exposure to ionizing radiation. Two different dose administration schedules (Ex-Rad I administered 24 and 36\u00a0h post-irradiation, and Ex-Rad II administered 48 and 60\u00a0h post-irradiation), were used and evaluated using a global molecular profiling approach. We observed alterations in biochemical pathways relating to inflammation and oxidative stress after radiation exposure that were alleviated in animals that received Ex-Rad I or Ex-Rad II. The results from this study lend credence to the possible radiomitigative effects of this drug possibly via a dampening of metabolism-based tissue injury, thus aiding in recovery of vital, radiation-injured organ systems.<\/jats:p>","DOI":"10.1038\/s41598-021-91067-9","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T15:32:54Z","timestamp":1622561574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Analysis of the metabolomic profile in serum of irradiated nonhuman primates treated with Ex-Rad, a radiation countermeasure"],"prefix":"10.1038","volume":"11","author":[{"given":"Yaoxiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Y.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi O.","family":"Fatanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Seed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita K.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"91067_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/09553002.2017.1332438","volume":"93","author":"VK Singh","year":"2017","unstructured":"Singh, V. K. & Seed, T. M. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: Part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int. J. Radiat. Biol. 93, 851\u2013869. https:\/\/doi.org\/10.1080\/09553002.2017.1332438 (2017).","journal-title":"Int. J. Radiat. Biol."},{"key":"91067_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/09553002.2017.1332440","volume":"93","author":"VK Singh","year":"2017","unstructured":"Singh, V. K., Hanlon, B. K., Santiago, P. T. & Seed, T. M. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: Part III. Countermeasures under early stages of development along with \u201cstandard of care\u201d medicinal and procedures not requiring regulatory approval for use. Int. J. Radiat. Biol. 93, 885\u2013906. https:\/\/doi.org\/10.1080\/09553002.2017.1332440 (2017).","journal-title":"Int. J. Radiat. Biol."},{"key":"91067_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/09553002.2017.1338782","volume":"93","author":"VK Singh","year":"2017","unstructured":"Singh, V. K., Garcia, M. & Seed, T. M. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: Part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int. J. Radiat. Biol. 93, 870\u2013884. https:\/\/doi.org\/10.1080\/09553002.2017.1338782 (2017).","journal-title":"Int. J. Radiat. Biol."},{"key":"91067_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1517\/13543776.2014.964684","volume":"24","author":"VK Singh","year":"2014","unstructured":"Singh, V. K., Newman, V. L., Romaine, P. L., Wise, S. Y. & Seed, T. M. Radiation countermeasure agents: An update (2011\u20132014). Expert Opin. Ther. Pat. 24, 1229\u20131255. https:\/\/doi.org\/10.1517\/13543776.2014.964684 (2014).","journal-title":"Expert Opin. Ther. Pat."},{"key":"91067_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1667\/RR1367.1","volume":"171","author":"SP Ghosh","year":"2009","unstructured":"Ghosh, S. P. et al. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat. Res. 171, 173\u2013179. https:\/\/doi.org\/10.1667\/RR1367.1 (2009).","journal-title":"Radiat. Res."},{"key":"91067_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1269\/jrr.11191","volume":"53","author":"S Suman","year":"2012","unstructured":"Suman, S. et al. Radioprotective effects of ON 01210.Na upon oral administration. J. Radiat. Res. 53, 368\u2013376 (2012).","journal-title":"J. Radiat. Res."},{"key":"91067_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/jrr\/rrs001","volume":"53","author":"SP Ghosh","year":"2012","unstructured":"Ghosh, S. P. et al. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J. Radiat. Res. 53, 526\u2013536. https:\/\/doi.org\/10.1093\/jrr\/rrs001 (2012).","journal-title":"J. Radiat. Res."},{"key":"91067_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1748-717X-7-6","volume":"7","author":"S Suman","year":"2012","unstructured":"Suman, S., Maniar, M., Fornace, A. J. Jr. & Datta, K. Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiat. Oncol. 7, 6. https:\/\/doi.org\/10.1186\/1748-717X-7-6 (2012).","journal-title":"Radiat. Oncol."},{"key":"91067_CR9","doi-asserted-by":"publisher","first-page":"e58355","DOI":"10.1371\/journal.pone.0058355","volume":"8","author":"AD Kang","year":"2013","unstructured":"Kang, A. D. et al. ON01210.Na (Ex-RAD(R)) mitigates radiation damage through activation of the AKT pathway. PLoS\u00a0One 8, e58355. https:\/\/doi.org\/10.1371\/journal.pone.0058355 (2013).","journal-title":"PLoS\u00a0One"},{"key":"91067_CR10","unstructured":"Onconova Therapeutics Inc. Onconova Therapeutics, Inc. http:\/\/www.onconova.com\/product-pipeline\/recilisib.php (2014)."},{"key":"91067_CR11","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2009-09-241000","volume":"115","author":"MM Juntilla","year":"2010","unstructured":"Juntilla, M. M. et al. AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood 115, 4030\u20134038. https:\/\/doi.org\/10.1182\/blood-2009-09-241000 (2010).","journal-title":"Blood"},{"key":"91067_CR12","doi-asserted-by":"publisher","first-page":"33592","DOI":"10.1007\/s11356-020-09618-y","volume":"27","author":"AE Musa","year":"2020","unstructured":"Musa, A. E., Shabeeb, D., Okoro, N. O. E. & Agbele, A. T. Radiation protection by Ex-RAD: a systematic review. Environ. Sci. Pollut. Res. Int. 27, 33592\u201333600. https:\/\/doi.org\/10.1007\/s11356-020-09618-y (2020).","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"91067_CR13","doi-asserted-by":"publisher","first-page":"e1003123","DOI":"10.1371\/journal.pcbi.1003123","volume":"9","author":"S Li","year":"2013","unstructured":"Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 9, e1003123. https:\/\/doi.org\/10.1371\/journal.pcbi.1003123 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"91067_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1667\/RR15008.1","volume":"190","author":"AK Cheema","year":"2018","unstructured":"Cheema, A. K. et al. Proteomic changes in mouse spleen after radiation-induced injury and its modulation by gamma-tocotrienol. Radiat. Res. 190, 449\u2013463. https:\/\/doi.org\/10.1667\/RR15008.1 (2018).","journal-title":"Radiat. Res."},{"key":"91067_CR15","first-page":"377","volume":"37","author":"NN Dygalo","year":"1997","unstructured":"Dygalo, N. N., Sakharov, D. G. & Shishkina, G. T. Corticosterone and testosterone in the blood of adult rats: the effects of low doses and the times of the action of ionizing radiation during intrauterine development. Radiat. Biol. Radioecol. 37, 377\u2013381 (1997).","journal-title":"Radiat. Biol. Radioecol."},{"key":"91067_CR16","doi-asserted-by":"publisher","first-page":"19961","DOI":"10.1073\/pnas.1014465107","volume":"107","author":"NT Nguyen","year":"2010","unstructured":"Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 107, 19961\u201319966. https:\/\/doi.org\/10.1073\/pnas.1014465107 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"91067_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm.2092","volume":"16","author":"Y Wang","year":"2010","unstructured":"Wang, Y. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 16, 279\u2013285. https:\/\/doi.org\/10.1038\/nm.2092 (2010).","journal-title":"Nat. Med."},{"key":"91067_CR18","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.2174\/0929867324666170509120257","volume":"24","author":"T Zarnowski","year":"2017","unstructured":"Zarnowski, T. et al. Kynurenic acid and neuroprotective activity of the ketogenic diet in the eye. Curr. Med. Chem. 24, 3547\u20133558. https:\/\/doi.org\/10.2174\/0929867324666170509120257 (2017).","journal-title":"Curr. Med. Chem."},{"key":"91067_CR19","doi-asserted-by":"publisher","first-page":"22021","DOI":"10.1074\/jbc.M603503200","volume":"281","author":"J Wang","year":"2006","unstructured":"Wang, J. et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281, 22021\u201322028. https:\/\/doi.org\/10.1074\/jbc.M603503200 (2006).","journal-title":"J. Biol. Chem."},{"key":"91067_CR20","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1074\/jbc.RA118.007138","volume":"294","author":"D Tauber","year":"2019","unstructured":"Tauber, D. & Parker, R. 15-Deoxy-Delta(12,14)-prostaglandin J2 promotes phosphorylation of eukaryotic initiation factor 2alpha and activates the integrated stress response. J. Biol. Chem. 294, 6344\u20136352. https:\/\/doi.org\/10.1074\/jbc.RA118.007138 (2019).","journal-title":"J. Biol. Chem."},{"key":"91067_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1021\/tx700177j","volume":"21","author":"K Uchida","year":"2008","unstructured":"Uchida, K. & Shibata, T. 15-Deoxy-Delta(12,14)-prostaglandin J2: an electrophilic trigger of cellular responses. Chem. Res. Toxicol. 21, 138\u2013144. https:\/\/doi.org\/10.1021\/tx700177j (2008).","journal-title":"Chem. Res. Toxicol."},{"key":"91067_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1667\/RR14127.1","volume":"185","author":"VK Singh","year":"2016","unstructured":"Singh, V. K. et al. Radioprotective efficacy of gamma-tocotrienol in nonhuman primates. Radiat. Res. 185, 285\u2013298. https:\/\/doi.org\/10.1667\/RR14127.1 (2016).","journal-title":"Radiat. Res."},{"key":"91067_CR23","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council of the National Academy of Sciences","year":"2011","unstructured":"National Research Council of the National Academy of Sciences. Guide for the Care and Use of Laboratory Animals 8th edn. (National Academies Press, 2011).","edition":"8"},{"key":"91067_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HP.0000000000000776","volume":"115","author":"EL Pannkuk","year":"2018","unstructured":"Pannkuk, E. L., Laiakis, E. C., Fornace, A. J. Jr., Fatanmi, O. O. & Singh, V. K. A metabolomic serum signature from nonhuman primates treated with a radiation countermeasure, gamma-tocotrienol, and exposed to ionizing radiation. Health Phys. 115, 3\u201311. https:\/\/doi.org\/10.1097\/HP.0000000000000776 (2018).","journal-title":"Health Phys."},{"key":"91067_CR25","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0969-8043(00)00052-X","volume":"52","author":"V Nagy","year":"2000","unstructured":"Nagy, V. Accuracy considerations in EPR dosimetry. Appl. Radiat. Isot. 52, 1039\u20131050 (2000).","journal-title":"Appl. Radiat. Isot."},{"key":"91067_CR26","volume-title":"Standard Practice for Use of an Alanine-EPR Dosimetry System","author":"International Standardization Organization and ASTM International","year":"2013","unstructured":"International Standardization Organization and ASTM International. Standard Practice for Use of an Alanine-EPR Dosimetry System, Vol 7  (ASTM International, ISO and West Conshohocken, 2013)."},{"key":"91067_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12859-015-0562-8","volume":"16","author":"G Libiseller","year":"2015","unstructured":"Libiseller, G. et al. IPO: a tool for automated optimization of XCMS parameters. BMC Bioinform. 16, 118. https:\/\/doi.org\/10.1186\/s12859-015-0562-8 (2015).","journal-title":"BMC Bioinform."},{"key":"91067_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1021\/ac051437y","volume":"78","author":"CA Smith","year":"2006","unstructured":"Smith, C. A., Want, E. J., O\u2019Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779\u2013787. https:\/\/doi.org\/10.1021\/ac051437y (2006).","journal-title":"Anal. Chem."},{"key":"91067_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/nprot.2011.335","volume":"6","author":"WB Dunn","year":"2011","unstructured":"Dunn, W. B. et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060\u20131083. https:\/\/doi.org\/10.1038\/nprot.2011.335 (2011).","journal-title":"Nat. Protoc."},{"key":"91067_CR30","unstructured":"(NIST), N. I. o. S. a. T. NIST 2017 Tandem MS Library. (2017)."},{"key":"91067_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. Ser. B (Methodol.) 58, 267\u2013288. https:\/\/doi.org\/10.1111\/j.2517-6161.1996.tb02080.x (1996).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91067-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:10:06Z","timestamp":1670058606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91067-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91067"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91067-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11449"}}